Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy of Everolimus in Patients With HR+/HER2- High Risk Early Stage Breast Cancer

19 Feb 2021

Virtual

ESMO-Virtual-Plenary-2021-1000x1000px

On demand webcasts from ESMO Virtual Plenaries are open to all with at least a free ESMO account. Slides are available according to the presenters' agreement to release them.
Discussed abstracts are available to all after the end of the session.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Monthly presentations of the latest, original scientific data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.

Programme

  • Welcome and introduction of the faculty; Scientific background and context
    Rebecca Dent, National Cancer Centre Singapore, Singapore
  • Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer
    Thomas Bachelot, Centre Leon Berard, Lyon, France
  • Perspectives
    Peter Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, UK
  • Discussion and Q&A
    Faculty and online audience (via chat feature)

Read the abstract

Hide
Filter by:

There are 4 resources available

Critical analysis and perspectives

Presenter: Peter Schmid

Session: EFFICACY OF EVEROLIMUS IN PATIENTS WITH HR+/HER2- HIGH RISK EARLY STAGE BREAST CANCER

Resources:

Slides

Webcast

Discussion and Q&A

Presenter: Rebecca Dent

Session: EFFICACY OF EVEROLIMUS IN PATIENTS WITH HR+/HER2- HIGH RISK EARLY STAGE BREAST CANCER

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings